Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo.
To better understand the antigenic requirements for cross-presentation, we compared the in vivo efficiency of presentation of cell-associated vs soluble OVA with the OT-I (CD8) and OT-II (CD4) TCR transgenic lines. Cross-presentation of cell-associated OVA was very efficient, requiring as little as 21 ng of OVA to activate OT-II cells and 100-fold less to activate OT-I cells. In contrast, soluble OVA was presented inefficiently, requiring at least 10,000 ng OVA for activation of either T cell subset. Thus, cell-associated OVA was presented 500-fold more efficiently than soluble OVA to CD4 T cells and 50,000-fold more efficiently to CD8 T cells. These data, which represent the first quantitative in vivo analysis of cross-presentation, show that cell-associated OVA is very efficiently presented via the class I pathway.
Li
M
M
Immunology Division and Transplantation and Autoimmunity Division, The Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital, Parkville, Victoria, Australia.
Davey
G M
GM
Sutherland
R M
RM
Kurts
C
C
Lew
A M
AM
Hirst
C
C
Carbone
F R
FR
Heath
W R
WR
D000818:Animals; D017951:Antigen Presentation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007275:Injections, Intravenous; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000008:administration & dosage / Q000032:analysis / Q000276:immunology* / Q000378:metabolism*; D012995:Solubility; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010047:Ovalbumin